tiprankstipranks
Blurbs

SVB Securities Maintains a Hold Rating on Turning Point Therapeutics (TPTX)

SVB Securities analyst Andrew Berens maintained a Hold rating on Turning Point Therapeutics (TPTXResearch Report) on July 27. The company’s shares closed last Friday at $74.98, close to its 52-week high of $82.20.

According to TipRanks.com, Berens ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.6% and a 46.9% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Deciphera Pharmaceuticals.

Turning Point Therapeutics has an analyst consensus of Hold, with a price target consensus of $73.00.

See today’s best-performing stocks on TipRanks >>

Turning Point Therapeutics’ market cap is currently $3.72B and has a P/E ratio of -13.46.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TPTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. It focuses on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Read More on TPTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles